Tempus AI is considered a high-risk buy due to its advanced AI-enabled diagnostic platform, despite facing challenges in US healthcare reimbursement. The company collaborates with over 2,500 institutions to gather real-time clinical data on cancer patients, improving treatment matching and clinical research. Its main products include Genomics, Data, and Applications, which provide diagnostic tests, data licensing, and AI-driven patient-provider connections for clinical trials.